WallStSmart

Medtronic PLC (MDT)vsAvita Medical Ltd (RCEL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 49452% more annual revenue ($35.48B vs $71.61M). MDT leads profitability with a 13.0% profit margin vs -67.8%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

RCEL

Avoid

20

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -11.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for RCEL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

RCEL1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1310/10

Conservative balance sheet, low leverage

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

RCEL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$121.00M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-17.5%2/10

ROE of -17.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : RCEL

The strongest argument for RCEL centers on Debt/Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : RCEL

The primary concerns for RCEL are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MDT profiles as a value stock while RCEL is a turnaround play — different risk/reward profiles.

RCEL carries more volatility with a beta of 1.81 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Avita Medical Ltd

HEALTHCARE · MEDICAL DEVICES · USA

AVITA Medical Inc. is a commercial stage regenerative tissue company in the United States, Australia, and the United Kingdom. The company is headquartered in Valencia, California.

Visit Website →

Want to dig deeper into these stocks?